Western Blotting Market Is Expected To Generate Revenue Of USD 2,620.2 Mn By 2033, At 6.8% CAGR: Dimension Market Research.
18 sept. 2024 12h15 HE
|
Dimension Market Research
New York, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Overview The Global Western Blotting Market is expected to reach USD 1,455.4 million in 2024 which is further projected to grow up to USD 2,620.2...
Biognosys Enters Reselling Agreement for Spectronaut Proteomics Software with Leading Provider of Mass Spectrometry Systems
18 sept. 2024 10h00 HE
|
Biognosys AG
Biognosys Enters Reselling Agreement for Spectronaut® Proteomics Software with Leading Provider of Mass Spectrometry Systems
Vive Crop Protection Boasts Strong Growth in 2024
18 sept. 2024 09h27 HE
|
Vive Crop Protection
Vive Crop Protection boasts strong growth in 2024 fueled by
efficiency and product innovation.
Registration Now Open for the Keiretsu Forum 2024 Investor Capital Expo in Philadelphia
18 sept. 2024 07h07 HE
|
Keiretsu Forum Mid-Atlantic
PHILADELPHIA, Pa., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum, the world’s largest angel investor network, is pleased to announce that registration is now open for the 2024 Investor Capital...
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
18 sept. 2024 06h15 HE
|
MannKind
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical
Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension
for the Treatment
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
17 sept. 2024 09h00 HE
|
Athira Pharma, Inc.
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of...
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
17 sept. 2024 07h00 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Cell Expansion Market Size to Reach USD 40.1 billion, Advancing at a CAGR of 12.1% by 2034: Exclusive Report by Transparency Market Research, Inc.
17 sept. 2024 06h50 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The global cell expansion market (세포 확장 시장) is estimated to flourish at a CAGR of 12.1%...
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value
16 sept. 2024 16h26 HE
|
DSS, Inc.
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the...
Global Live Cell Imaging Market Report 2024-2029: Growing Adoption of High-Content Screening Techniques in Drug Discovery and Increasing Demand for Improved Understanding of Cellular Processes
16 sept. 2024 06h05 HE
|
Research and Markets
Dublin, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The "Live Cell Imaging Global Market Report 2024-2029" report has been added to ResearchAndMarkets.com's offering. The global market for live cell...